Diffusion a validation process : learning from patient innovators

• Autor(a) principal: Nogueira, Tomás Fidélis da Silva
• Data de Publicação: 2013
• Tipo de documento: Dissertação
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.14/17590
• topic: User innovation; Patient innovation; Diffusion; Validation of health-care innovations; Observational trials; Domínio/Área Científica::Ciências Sociais::Economia e Gestão

Randomized, controlled clinical trials, although important for ensuring safety and efficacy, are criticized for being an inadequate validation process for certain medical innovation modalities and conditions. The main limitations and causes for critique are high costs, long duration, low patient recruitment, design rigidity and ethical issues. At the same time, there is growing evidence that patients and their family members innovate in treatments, therapies, and medical devices. These patient innovators are increasingly recognized as an important source of innovation. Although there is a fairly complex structure developed to formally validate healthcare products, little is known about the paths patient innovators take to validate their solutions before involving health regulators. In this context, we attempt to answer the following research questions: What are the patterns of the validation processes undertaken by patient innovators for their innovations? How can current practices of patient innovation validation be improved from its comparison with observational studies and clinical trials? To address these questions, we study cases of patient innovators who attempted to share their innovations with other patients. More specifically, we structure the observed processes of patient innovation diffusion as a process model for an iterative observational trial process in which incremental validation of the innovation is performed by diffusing it to other patients. We contrast this process with a general streamlined process of randomized clinical trials. We argue learning from the patient innovators practices is important for discussing viable frameworks and structures for improving the safety and efficacy of these processes. We discuss related implications to innovation research, management and policy.